IRulya Therapeutics Balance Sheet
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRulya Therapeutics financial position
At the end of fiscal 2025, IRulya Therapeutics reported total assets of $93.5 million, down 18.3% from a year earlier against total liabilities of $129.2 million. Shareholders' equity was negative at -$35.7 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $5.8 million in cash and equivalents against $18.0 million of debt, a net debt position of $12.2 million.
The current ratio (current assets divided by current liabilities) was 0.53, meaning short-term obligations exceed short-term assets.
Summary generated from market data by MetaCap's automated system. Methodology
IRulya Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 5.81M | 6.21M | 20.75M | 40.59M | 29.45M | 66.84M | 51.21M | 24.87M |
| Short-Term Investments | 11.94M | 34.57M | 54.31M | 45.60M | 37.08M | 66.98M | 48.65M | 46.84M |
| Receivables | — | — | — | 0 | — | — | — | — |
| Total Current Assets | 22.90M | 44.04M | 77.44M | 93.75M | 111.67M | 137.86M | 106.06M | 72.58M |
| Property, Plant & Equipment | 595.00K | 315.00K | 234.00K | 393.00K | 263.00K | 427.00K | 709.00K | 283.00K |
| Goodwill | — | 0 | 17.63M | 0 | 0 | — | — | — |
| Intangible Assets | 67.82M | 60.05M | 63.67M | 5.90M | 0 | — | — | — |
| Long-Term Investments | — | — | 0 | 3.58M | 19.93M | 50.46M | 16.76M | — |
| Total Assets | 93.52M | 114.48M | 167.90M | 103.91M | 133.23M | 189.47M | 124.37M | 72.88M |
| Accounts Payable | 2.22M | 2.90M | 2.03M | 570.00K | 4.91M | 3.56M | 3.08M | 495.00K |
| Short-Term Debt | 18.03M | 0 | — | — | — | — | — | — |
| Total Current Liabilities | 43.23M | 7.28M | 9.57M | 3.07M | 14.22M | 17.00M | 8.89M | 1.46M |
| Long-Term Debt | 0 | 14.32M | 13.43M | 0 | — | — | — | — |
| Total Liabilities | 129.24M | 84.33M | 82.82M | 3.32M | 14.64M | 17.20M | 8.89M | 1.46M |
| Shareholders' Equity | -35.71M | 30.15M | 85.08M | 100.59M | 118.59M | 172.26M | 115.48M | -32.63M |
| Retained Earnings | -460.45M | -376.47M | -319.64M | -288.26M | -236.60M | -146.65M | -69.81M | -32.83M |
| Total Debt | 18.03M | 14.32M | 13.43M | 0 | — | — | — | — |
| Net Cash (Debt) | -274.00K | 26.46M | 61.63M | 86.19M | 66.53M | 133.82M | 99.86M | 71.72M |
| Shares Outstanding | 278.63K | 44.00M | 42.97M | 36.14M | 30.07M | 29.54M | 26.87M | 3.41M |
This table shows 8 annual periods of IRulya Therapeutics's balance sheet, from FY 2025 back to FY 2018, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a balance sheet?